资讯
Zakaria and colleagues describe the case of a previously healthy 29-year-old man with renal infarction. The nonspecific nature of his presenting symptoms caused a delay in diagnosis. The authors ...
Acute renal infarction (ARI) is a rare disease that is often misdiagnosed initially because of its nonspecific presentation. In this Case Study, Nasser and colleagues describe a patient with ARI ...
In patients with cardiac amyloidosis, renal infarction is associated with acute kidney injury according to a new study in Mayo Clinic Proceedings, published by Elsevier.
Acute kidney injury in a context of cardiac amyloidosis may be due to renal infarction, report scientists in a new study published in Mayo Clinic Proceedings Rochester, MN, May 15, 2019 - Systemic ...
First study of its kind finds renal infarction in cardiac amyloidosis may be more common than previously thought, especially in patients with acute kidney injury, but an expert questions the results.
For patients with acute MI at increased risk for HF, empagliflozin showed cardiorenal benefits and was safe to initiate early ...
Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with acute myocardial infarction (MI), according to a study published ...
The presence of silent cerebral infarction (SCI) may predict an increased risk for worsening kidney function in patients with type 2 diabetes.
People with kidney disease undergo balloon dilation treatment after myocardial infarction less frequently, and therefore have a poorer prognosis, researchers say.
Total adverse events of heart failure or all-cause mortality were reduced with empagliflozin, regardless of kidney function. (HealthDay News) — Empagliflozin has kidney protective effects and ...
Finerenone may lower risks for kidney and cardiovascular events for adults with chronic kidney disease and type 2 diabetes, ...
15 天
HealthDay on MSNEmpagliflozin Has Kidney Protective Effects in Acute Myocardial InfarctionTotal adverse events of heart failure or all-cause mortality were reduced with empagliflozin, regardless of kidney function.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果